Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
Abstract
Immune escape is a crucial feature of cancer progression about which little is known. Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can facilitate immune escape. Not known is how IDO becomes elevated or whether IDO inhibitors will be useful for cancer treatment. Here we show that IDO is under genetic control of Bin1, which is attenuated in many human malignancies. Mouse knockout studies indicate that Bin1 loss elevates the STAT1- and NF-kappaB-dependent expression of IDO, driving escape of oncogenically transformed cells from T cell-dependent antitumor immunity. In MMTV-Neu mice, an established breast cancer model, we show that small-molecule inhibitors of IDO cooperate with cytotoxic agents to elicit regression of established tumors refractory to single-agent therapy. Our findings suggest that Bin1 loss promotes immune escape in cancer by deregulating IDO and that IDO inhibitors may improve responses to cancer chemotherapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Studies of IDO pathway blockade with radiation, chemotherapy, and tumor vaccines suggest improvement relative to those treatments alone.
“Studies of IDO pathway blockade with radiation, chemotherapy and tumor vaccines suggest an improvement relative to those treatments alone (53,54).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [53]
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219 · see citing works
Current Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,574 · see citing works
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589 · see citing works
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · see citing works
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D., Shafizadeh, E., Attwood, J., Bondarev, I., Pashine, A., & Mellor, A. (1999) · Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,721 · see citing works
BAR Domains as Sensors of Membrane Curvature: The Amphiphysin BAR Structure
Peter, B. J., Kent, H. M., Mills, I. G., Vallis, Y., Butler, P. J. G., Evans, P. R., & McMahon, H. T. (2003) · Science · doi:10.1126/science.1092586 · Cited by 1,706 · see citing works
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1252 · Cited by 1,567 · see citing works
Current protocols in immunology
Nezlin, R. S. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90114-d · Cited by 1,413 · see citing works
Colorectal carcinoma antigens detected by hybridoma antibodies
Koprowski, H., Steplewski, Z., Mitchell, K. F., Herlyn, M., Herlyn, D., & Fuhrer, P. (1979) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01542654 · Cited by 1,360 · see citing works
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,173 · see citing works
Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase
Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R. E., et al. (2002) · Science · doi:10.1126/science.1073514 · Cited by 1,028 · see citing works
Tolerance, DCs and tryptophan: much ado about IDO
Grohmann, U. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00072-3 · Cited by 766 · see citing works
Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., DeSolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., et al. (1995) · Nature Medicine · doi:10.1038/nm0895-792 · Cited by 540 · see citing works
APPL Proteins Link Rab5 to Nuclear Signal Transduction via an Endosomal Compartment
Miączyńska, M., Christoforidis, S., Giner, A., Shevchenko, A., Uttenweiler‐Joseph, S., Habermann, B. H., Wilm, M. S., Parton, R. G., & Zerial, M. (2004) · Cell · doi:10.1016/s0092-8674(04)00117-5 · Cited by 536 · see citing works
Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 455 · see citing works
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 414 · see citing works
BIN1 is a novel MYC–interacting protein with features of a tumour suppressor
Sakamuro, D., Elliott, K. J., Wechsler-Reya, R., & Prendergast, G. C. (1996) · Nature Genetics · doi:10.1038/ng0996-69 · Cited by 387 · see citing works
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A. B., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 366 · see citing works
SOME VIRUS ISOLATIONS FROM COMMON COLDS
Tyrrell, D. A. J., & PARSONS, R. (1960) · The Lancet · doi:10.1016/s0140-6736(60)90168-9 · Cited by 337 · see citing works
CtBP/BARS induces fission of Golgi membranes by acylating lysophosphatidic acid
Weigert, R., Silletta, M. G., Spanò, S., Turacchio, G., Cericola, C., Colanzi, A., Senatore, S., Mancini, R., Polishchuk, E. V., Salmona, M., et al. (1999) · Nature · doi:10.1038/46587 · Cited by 330 · see citing works
N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma
Bernards, R., Dessain, S. K., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90509-x · Cited by 301 · see citing works
c‐myc down‐regulates class I HLA expression in human melanomas.
Versteeg, R., Noordermeer, I., Krüse-Wolters, M., Ruiter, D. J., & Schrier, P. I. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02909.x · Cited by 253 · see citing works
The amphiphysin family of proteins and their role in endocytosis at the synapse
Wigge, P., & McMahon, H. T. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01264-8 · Cited by 247 · see citing works
Ge, K., DuHadaway, J. B., Du, W., Herlyn, M., Rodeck, U., & Prendergast, G. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9689 · Cited by 196 · see citing works
Meloni, A. R., Smith, E., & Nevins, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9574 · Cited by 183 · see citing works
Boyland, E. J., & Williams, D. C. (1956) · Biochemical Journal · doi:10.1042/bj0640578 · Cited by 180 · see citing works
Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays.
Huang, H., Colella, S., Kurrer, M. O., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2000) · PubMed · Cited by 169 · see citing works
Cytoplasmic transport of Stat3 by receptor‐mediated endocytosis
Bild, A. H., Turkson, J., & Jove, R. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf351 · Cited by 150 · see citing works
Macrophages as accessory cells for class I MHC-restricted immune responses
Debrick, J. E., Campbell, P., & Staerz, U. D. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.9.2846 · Cited by 148 · see citing works
Muller, A. J., Baker, J. F., DuHadaway, J. B., Ge, K., Farmer, G., Donover, P. S., Meade, R., Reid, C., Grzanna, R., Roach, A. H., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.12.4295-4306.2003 · Cited by 139 · see citing works
Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms
Elliott, K., Sakamuro, D., Basu, A., Du, W., Wunner, W. H., Staller, P., Gaubatz, S., Zhang, H., Prochownik, E. V., Eilers, M., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202670 · Cited by 120 · see citing works
A Role for the Putative Tumor Suppressor Bin1 in Muscle Cell Differentiation
Wechsler‐Reya, R. J., Elliott, K. J., & Prendergast, G. C. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.566 · Cited by 113 · see citing works
The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program
Elliott, K., Ge, K., Du, W., & Prendergast, G. C. (2000) · Oncogene · doi:10.1038/sj.onc.1203681 · Cited by 106 · see citing works
Nucleocytoplasmic Shuttling of Endocytic Proteins
Vecchi, M., Polo, S., Poupon, V., van de Loo, J.-W., Benmerah, A., & Fiore, P. P. D. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.7.1511 · Cited by 96 · see citing works
Expression and Purification of Recombinant Human Indoleamine 2,3-Dioxygenase
Littlejohn, T. K., Takikawa, O., Skylas, D. J., Jamie, J. F., Walker, M. J., & Truscott, R. J. W. (2000) · Protein Expression and Purification · doi:10.1006/prep.2000.1214 · Cited by 91 · see citing works
Zelhof, A. C., Bao, H., Hardy, R. W., Razzaq, A., Zhang, B., & Doe, C. Q. (2001) · Development · doi:10.1242/dev.128.24.5005 · Cited by 86 · see citing works
Leprince, C., Scolan, E. L., Meunier, B., Fraisier, V., Brandon, N., de Gunzburg, J., & Camonis, J. (2003) · Journal of Cell Science · doi:10.1242/jcs.00403 · Cited by 75 · see citing works
Bin1 mediates apoptosis by c-Myc in transformed primary cells.
DuHadaway, J. B., Sakamuro, D., Ewert, D. L., & Prendergast, G. C. (2001) · PubMed · Cited by 73 · see citing works
TRYPTOPHAN METABOLISM IN CARCINOMA OF THE BREAST
ROSE, D. (1967) · The Lancet · doi:10.1016/s0140-6736(67)91301-3 · Cited by 72 · see citing works
Bártková, J., Thullberg, M., Meyts, E. R., Skakkebæk, N. E., & Bartek, J. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000201)85:3 · Cited by 70 · see citing works
Mammalian cell transformation and aneuploidy induced by five bisphenols
Tsutsui, T., Tamura, Y., Suzuki, A., Hirose, Y., Kobayashi, M., Nishimura, H., Metzler, M., & Barrett, J. C. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000415)86:2 · Cited by 70 · see citing works
Analysis of Transcription Factors Regulating Induction of Indoleamine 2,3-Dioxygenase by IFN- gamma
Du, M. X., Sotero-Esteva, W. D., & Taylor, M. W. (2000) · Journal of Interferon & Cytokine Research · doi:10.1089/107999000312531 · Cited by 66 · see citing works
Tajiri, T., Liu, X., Thompson, P. M., Tanaka, S., Suita, S., Zhao, H., Maris, J. M., Prendergast, G. C., & Hogarty, M. D. (2003) · PubMed · Cited by 61 · see citing works
Enhancement of tumor radioresponse by docetaxel: Involvement of immune system
Mason, K. A., Staab, A., Hunter, N. R., McBride, W. H., Petersen, S. H., Terry, N. H. A., & Milas, L. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.3.599 · Cited by 55 · see citing works
DuHadaway, J. B., Lynch, F. J., Brisbay, S., Bueso‐Ramos, C., Troncoso, P., McDonnell, T., & Prendergast, G. C. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10380 · Cited by 49 · see citing works
In Vivo Depletion of CD 4‐ and CD 8‐Specific T Cells
Kruisbeek, A. M. (1992) · Current Protocols in Immunology · doi:10.1002/0471142735.im0401s01 · Cited by 46 · see citing works
(1997) · PubMed · Cited by 45 · see citing works
Brandt, R., Wong, A. M.-L., & Hynes, N. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204709 · Cited by 44 · see citing works
Effect of elevated levels of ornithine decarboxylase on cell cycle progression in skin.
Gilmour, S. K., Birchler, M., Smith, M. K., Rayca, K., & Mostochuk, J. (1999) · PubMed · Cited by 36 · see citing works
Robson, W. L. M. (1928) · Biochemical Journal · doi:10.1042/bj0221157 · Cited by 29 · see citing works
Routhier, E., Donover, P. S., & Prendergast, G. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206162 · Cited by 28 · see citing works
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto‐Ward, E., & Prendergast, G. C. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.12.1232 · Cited by 25 · see citing works
Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1
DuHadaway, J. B., Du, W., Donover, P. S., Baker, J. F., Liu, A., Sharp, D. M., Muller, A. J., & Prendergast, G. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206481 · Cited by 19 · see citing works
Shimizu, F., Satoh, J., Tada, M., & Kumagai, K. (1978) · Infection and Immunity · doi:10.1128/iai.22.3.752-757.1978 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury
Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny, G. D., Mitchison, T. J., Moskowitz, M. A., & Yuan, J. (2005) · Nature Chemical Biology · doi:10.1038/nchembio711 · Cited by 3,068 · see citing works
Understanding the Intersections between Metabolism and Cancer Biology
Heiden, M. G. V., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,316 · see citing works
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898 · see citing works
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586 · see citing works
Genetics and biology of pancreatic ductal adenocarcinomaPreprint
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. M., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,570 · see citing works
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,451 · see citing works
Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism
Gao, J., Xu, K., Liu, H., Liu, G., Bai, M., Peng, C., Li, T., & Yin, Y. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00013 · Cited by 1,313 · see citing works
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,074 · see citing works
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.
Allavena, P., Sica, A., Solinas, G., Porta, C., & Mantovani, A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.07.004 · Cited by 1,044 · see citing works
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037 · see citing works
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,054 · see citing works
Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6752 · Cited by 1,042 · see citing works
Tryptophan metabolism in health and disease
Chen, X., Li, G., Zheng, Q., Gu, X., Shi, Q., Su, Y., Chu, Q., Yuan, X., Bao, Z., Lu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.004 · Cited by 1,008 · see citing works
Regulation of the immune response by the aryl hydrocarbon receptor
Gutiérrez-Vázquez, C., & Quintana, F. J. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.012 · Cited by 985 · see citing works
The Sorcerer II Global Ocean Sampling Expedition: Expanding the Universe of Protein Families
Yooseph, S., Sutton, G., Rusch, D. B., Halpern, A. L., Williamson, S. J., Remington, K., Eisen, J. A., Heidelberg, K. B., Manning, G., Li, W., et al. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050016 · Cited by 905 · see citing works
Role of tumor-associated macrophages in tumor progression and invasion
Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9001-7 · Cited by 885 · see citing works
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865 · see citing works
Sharma, M. D., Baban, B., Chandler, P., Hou, D., Singh, N., Yagita∥, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 791 · see citing works
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & den Eynde, B. J. V. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 708 · see citing works
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Pallotta, M. T., Orabona, C., Volpi, C., Vacca, C., Belladonna, M. L., Bianchi, R., Servillo, G., Brunacci, C., Calvitti, M., Bicciato, S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2077 · Cited by 705 · see citing works
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641 · see citing works
The Yin‐Yang of tumor‐associated macrophages in neoplastic progression and immune surveillance
Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00607.x · Cited by 650 · see citing works
Holmgaard, R., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 633 · see citing works
Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y.-Q., & Guillemin, G. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 589 · see citing works
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614 · see citing works
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 606 · see citing works
Cancer related inflammation: the macrophage connection
Sica, A., Allavena, P., & Mantovani, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.028 · Cited by 601 · see citing works
Hou, D., Muller, A. J., Sharma, M. D., DuHadaway, J. B., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586 · see citing works
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., Plaen, E. D., Uyttenhove, C., Wouters, J., Masereel, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113873109 · Cited by 576 · see citing works
Basit, F., van Oppen, L. M. P. E., Schöckel, L., Bossenbroek, H. M., Vries, S. E. V. E., Hermeling, J. C., Grefte, S., Kopitz, C., Héroult, M., Willems, P. H. G. M., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.133 · Cited by 569 · see citing works
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Garrido‐Laguna, I., & Hidalgo, M. M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.53 · Cited by 565 · see citing works
Discovery of IDO1 Inhibitors: From Bench to Bedside
Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 563 · see citing works
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M., Thomas, B. A., Rupar, M. J., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 549 · see citing works
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527 · see citing works
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik‐Nayak, L., Laury‐Kleintop, L. D., Metz, R. A., & Muller, A. J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 484 · see citing works
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J. M. B., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 471 · see citing works
Metz, R. A., DuHadaway, J. B., Kamasani, U. R., Laury‐Kleintop, L. D., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1872 · Cited by 468 · see citing works
Takahashi, N., Duprez, L., Grootjans, S., Cauwels, A., Nerinckx, W., DuHadaway, J. B., Goossens, V, Roelandt, R., Van Hauwermeiren, F., Libert, C., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.176 · Cited by 465 · see citing works
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Shi, Y.-F., Du, L., Lin, L.-Y., & Wang, Y. (2016) · Nature reviews. Drug discovery · doi:10.1038/nrd.2016.193 · Cited by 409 · see citing works
IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation
Puccetti, P., & Grohmann, U. (2007) · Nature reviews. Immunology · doi:10.1038/nri2163 · Cited by 457 · see citing works
Targeting the IDO1 pathway in cancer: from bench to bedside
Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 449 · see citing works
Biologically active quinoline and quinazoline alkaloids part I
Shang, X., Morris-Natschke, S. L., Liu, Y., Guo, X., Xu, X., Goto, M., Li, J., Yang, G., & Lee, K. (2017) · Medicinal Research Reviews · doi:10.1002/med.21466 · Cited by 446 · see citing works
Regulation of HIF-1α Stability through S-Nitrosylation
Li, F., Sonveaux, P., Rabbani, Z. N., Liu, S., Yan, B., Huang, Q., Vujašković, Ž., Dewhirst, M. W., & Li, C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.024 · Cited by 439 · see citing works
Miyagi, Y., Higashiyama, M., Gochi, A., Akaike, M., Ishikawa, T., Miura, T., Saruki, N., Bando, E., Kimura, H., Imamura, F., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024143 · Cited by 435 · see citing works
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H., Opelz, G., & Terness, P. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2639 · Cited by 421 · see citing works
Labadie, B. W., Bao, R., & Luke, J. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2882 · Cited by 413 · see citing works
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2250 · Cited by 404 · see citing works
Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 399 · see citing works
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393 · see citing works
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Godin-Ethier, J., Hanafi, L., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 398 · see citing works
Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N., Yanaihara, N., Yamada, K., Takikawa, O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2671 · Cited by 391 · see citing works
Metz, R. A., Rust, S., DuHadaway, J. B., Mautino, M. R., Munn, D. H., Vahanian, N. N., Link, C. J., & Prendergast, G. C. (2012) · OncoImmunology · doi:10.4161/onci.21716 · Cited by 389 · see citing works
Thomas, S., Izard, J., Walsh, E. K., Batich, K. A., Chongsathidkiet, P., Clarke, G. A., Sela, D. A., Muller, A. J., Mullin, J. M., Albert, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2929 · Cited by 369 · see citing works
Peng, J., Xiao, Y., Li, W., Yang, Q., Tan, L., Jia, Y., Qu, Y., & Qian, Z. (2018) · Advanced Science · doi:10.1002/advs.201700891 · Cited by 364 · see citing works
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355 · see citing works
Yang, L., Chu, Z., Liu, M., Zou, Q., Li, J., Liu, Q., Wang, Y., Wang, T., Xiang, J., & Wang, B. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01453-1 · Cited by 362 · see citing works
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Mbongue, J., Nicholas, D., Torrez, T., Kim, N.-S., Firek, A., & Langridge, W. (2015) · Vaccines · doi:10.3390/vaccines3030703 · Cited by 351 · see citing works
“For some time, the significance of IDO promotion of cancer survival was questioned by its observed function in the prevention of allogenic rejection and by the evidence that IDO is overexpressed in most tumors and tumor draining lymph nodes [106,107].”
BackgroundCancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
Platten, M., Doeberitz, N. V. K., Oezen, I., Wick, W., & Ochs, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00673 · Cited by 342 · see citing works
Twelve immunotherapy drugs that could cure cancers
Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 339 · see citing works
Ye, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z. (2016) · ACS Nano · doi:10.1021/acsnano.6b04989 · Cited by 340 · see citing works
Cytokines as a key component of cancer-related inflammation
Germano, G., Allavena, P., & Mantovani, A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.014 · Cited by 331 · see citing works
Tumor promoting role of anti-tumor macrophages in tumor microenvironment
Goswami, K. K., Ghosh, T., Ghosh, S., Sarkar, M., Bose, A., & Baral, R. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.04.005 · Cited by 334 · see citing works
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Sautès‐Fridman, C., Tartour, É., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 327 · see citing works
Immune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325 · see citing works
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 325 · see citing works
Necroptosis in the Pathophysiology of Disease
Khoury, M. K., Gupta, K., Franco, S. R., & Liu, B. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.10.012 · Cited by 326 · see citing works
Characterization of the Kynurenine Pathway in Human Neurons
Guillemin, G. J., Cullen, K. M., Lim, C. K., Smythe, G. A., Garner, B., Kapoor, V., Takikawa, O., & Brew, B. J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4101-07.2007 · Cited by 325 · see citing works
Litzenburger, U. M., Opitz, C. A., Sahm, F., Rauschenbach, K. J., Trump, S., Winter, M., Ott, M., Ochs, K., Lutz, C., Liu, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1637 · Cited by 322 · see citing works
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Smith, C., Chang, M. Y., Parker, K. H., Beury, D. W., DuHadaway, J. B., Flick, H. E., Boulden, J., Sutanto‐Ward, E., Soler, A. P., Laury‐Kleintop, L. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0014 · Cited by 320 · see citing works
Emerging targets in cancer immunotherapy
Burugu, S., Dancsok, A. R., & Nielsen, T. O. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.001 · Cited by 316 · see citing works
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy
Grohmann, U., Volpi, C., Fallarino, F., Bozza, S., Bianchi, R., Vacca, C., Orabona, C., Belladonna, M. L., Ayroldi, E., Nocentini, G., et al. (2007) · Nature Medicine · doi:10.1038/nm1563 · Cited by 316 · see citing works
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314 · see citing works
Control of immune response by amino acid metabolism
Grohmann, U., & Bronte, V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00915.x · Cited by 311 · see citing works
D'Amato, N. C., Rogers, T. J., Gordon, M. A., Greene, L. I., Cochrane, D. R., Spoelstra, N. S., Nemkov, T. G., D'Alessandro, A., Hansen, K. C., & Richer, J. K. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2011 · Cited by 294 · see citing works
Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection
Zhang, J., Chen, C., Li, A., Jing, W., Sun, P., Huang, X., Liu, Y., Zhang, S., Du, W., Zhang, R., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00843-7 · Cited by 305 · see citing works
Combinational strategy for high-performance cancer chemotherapy
Qin, S., Cheng, Y., Lei, Q., Zhang, A., & Zhang, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.027 · Cited by 301 · see citing works
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H. D. P., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0106-z · Cited by 275 · see citing works
Rocha, J., Peixe, L. M. S. V., Gomes, N. C. M., & Calado, R. (2011) · Marine Drugs · doi:10.3390/md9101860 · Cited by 274 · see citing works
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Comas, D. R., Astoul, P. J., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273 · see citing works
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
Wu, A. A., Drake, V. E., Huang, H.-S., Chiu, S., & Zheng, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016700 · Cited by 274 · see citing works
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
Prendergast, G. C., Malachowski, W. P., Mondal, A., Scherle, P., & Muller, A. J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.004 · Cited by 274 · see citing works
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Brochez, L., Chevolet, I., & Krüse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 268 · see citing works
Necrostatin-1 and necroptosis inhibition: Pathophysiology and therapeutic implications
Cao, L., & Mu, W. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105297 · Cited by 269 · see citing works
Immune Suppression in the Tumor Microenvironment
Gajewski, T. F., Meng, Y., & Harlin, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199193.29048.56 · Cited by 261 · see citing works
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
Muller, A. J., Manfredi, M. G., Zakharia, Y., & Prendergast, G. C. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0702-0 · Cited by 265 · see citing works
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1929 · Cited by 263 · see citing works
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2008) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 259 · see citing works
Molecules in focus: Indoleamine 2,3-dioxygenase
King, N. J. C., & Thomas, S. R. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.004 · Cited by 260 · see citing works
The tumor‐draining lymph node as an immune‐privileged site
Munn, D. H., & Mellor, A. L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00444.x · Cited by 251 · see citing works
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., Takahashi, N. K., Terauchi, M., Nawa, A., Nomura, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603477 · Cited by 247 · see citing works
Self‐Amplified Drug Delivery with Light‐Inducible Nanocargoes to Enhance Cancer Immunotherapy
Feng, B., Hou, B., Xu, Z., Saeed, M., Yu, H., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201902960 · Cited by 244 · see citing works
The immune system and inflammation in breast cancer
Jiang, X., & Shapiro, D. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.06.003 · Cited by 243 · see citing works
Indoleamine 2,3‐dioxygenase 1 (IDO1): an up‐to‐date overview of an eclectic immunoregulatory enzyme
Pallotta, M. T., Rossini, S., Suvieri, C., Coletti, A., Orabona, C., Macchiarulo, A., Volpi, C., & Grohmann, U. (2021) · FEBS Journal · doi:10.1111/febs.16086 · Cited by 243 · see citing works
Muller, A. J., Sharma, M. D., Chandler, P., DuHadaway, J. B., Everhart, M. E., Johnson, B. A., Kahler, D. J., Pihkala, J. P. S., Soler, A. P., Munn, D. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806173105 · Cited by 242 · see citing works
von Bergwelt‐Baildon, M. S., Popov, A., Šarić, T., Chemnitz, J. M., Claßen, S., Stoffel, M. S., Fiore, F., Roth, U., Beyer, M., Debey, S., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3507 · Cited by 237 · see citing works
Ino, K., Yamamoto, E., Shibata, K., Kajiyama, H., Yoshida, N., Terauchi, M., Nawa, A., Nagasaka, T., Takikawa, O., & Kikkawa, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4144 · Cited by 241 · see citing works
Role of indoleamine 2,3-dioxygenase in health and disease
Yeung, A. W. S., Terentis, A. C., King, N. J. C., & Thomas, S. R. (2015) · Clinical Science · doi:10.1042/cs20140392 · Cited by 235 · see citing works
Golan‐Gerstl, R., Cohen, M., Shilo, A., Suh, S., Bakàcs, A., Coppola, L., & Karni, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4410 · Cited by 232 · see citing works
Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
van Baren, N., & den Eynde, B. J. V. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00034 · Cited by 230 · see citing works
- Authors
- Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C.
- Affiliations
- Lankenau Institute for Medical Research (US)
- Thomas Jefferson University (US)
- Corresponding author
- Prendergast, George C
- Venue
- Nature Medicine
- Published
- 2005-02-13
- Volume
- 11
- Issue
- 3
- Pages
- 312-319
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2090410108
- Cited by
- 1,064
- References
- 54
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 41 · 2023: 53 · 2022: 45 · 2021: 53 · 2020: 59 · 2019: 59 · 2018: 65 · 2017: 72 · 2016: 54 · 2015: 63 · 2014: 51 · 2013: 53 · 2012: 56
- FWCI
- 23.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- indoleamine 2,3-dioxygenase, BIN1, IDO inhibitors, tumor immune evasion, antitumor immunity, STAT1, NF-κB, MMTV-Neu mice, breast cancer, combination chemotherapy, tumor immunosuppression, gene knockout
- MeSH terms
- Animals, Cell Transformation, Neoplastic, DNA-Binding Proteins, Drug Synergism, Enzyme Inhibitors, Indoles, Interferon-gamma, Mammary Neoplasms, Experimental, Molecular Sequence Data, Nerve Tissue Proteins, Thiohydantoins, Tryptophan Oxygenase, Trans-Activators, NF-kappa B, Paclitaxel, Tumor Escape, Tumor Suppressor Proteins, Adaptor Proteins, Signal Transducing, Indoleamine-Pyrrole 2,3,-Dioxygenase, STAT1 Transcription Factor, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
